SS
DMAAU

Steve Schonfeld’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Steve Schonfeld’s Portfolio DMAAU Stock Details DMAAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-234,831
Closed -$2.39M – 2676
2025
Q1 		$2.39M Buy
+234,831
New +$2.37M 0.01% 875

Other funds holding DMAAU

RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $226M AUM 6.92% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Steve Schonfeld's DMAAU Position: Q2 2025 in Review

Steve Schonfeld sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q2 2025, closing a stake of 234,831 shares — an estimated $2.39M sold.

Steve Schonfeld first reported a position in DMAAU in Q1 2025 and held it in 1 quarter. The position peaked at $2.39M in Q1 2025. 9 funds tracked by Wall St. Rank hold DMAAU as of Q2 2025.

  • Steve Schonfeld reported no remaining Drugs Made In America Acquisition Corp Units position as of Q2 2025 after selling out during the quarter.
  • Steve Schonfeld sold 234,831 Drugs Made In America Acquisition Corp Units shares in Q2 2025, an estimated $2.39M.
  • Steve Schonfeld first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 1 quarter.
  • Steve Schonfeld's Drugs Made In America Acquisition Corp Units position peaked at $2.39M in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.